Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1260253.RAZ4beLQisSznh3rql_UtgYHVzf9d2WM6PGZnXWSpe5Sc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1260253.RAZ4beLQisSznh3rql_UtgYHVzf9d2WM6PGZnXWSpe5Sc130_assertion type Assertion NP1260253.RAZ4beLQisSznh3rql_UtgYHVzf9d2WM6PGZnXWSpe5Sc130_head.
- NP1260253.RAZ4beLQisSznh3rql_UtgYHVzf9d2WM6PGZnXWSpe5Sc130_assertion description "[Eligibility included AML in first complete remission (CR1) with adverse risk karyotype (n = 8), fms-related tyrosine kinase 3-internal tandem duplication (FLT3-ITD) (n = 5), age ?60 years (n = 31) or AML in second remission (CR2) (n = 14).Dose-limiting toxicity was not reached.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1260253.RAZ4beLQisSznh3rql_UtgYHVzf9d2WM6PGZnXWSpe5Sc130_provenance.
- NP1260253.RAZ4beLQisSznh3rql_UtgYHVzf9d2WM6PGZnXWSpe5Sc130_assertion evidence source_evidence_literature NP1260253.RAZ4beLQisSznh3rql_UtgYHVzf9d2WM6PGZnXWSpe5Sc130_provenance.
- NP1260253.RAZ4beLQisSznh3rql_UtgYHVzf9d2WM6PGZnXWSpe5Sc130_assertion SIO_000772 25643589 NP1260253.RAZ4beLQisSznh3rql_UtgYHVzf9d2WM6PGZnXWSpe5Sc130_provenance.
- NP1260253.RAZ4beLQisSznh3rql_UtgYHVzf9d2WM6PGZnXWSpe5Sc130_assertion wasDerivedFrom befree-2016 NP1260253.RAZ4beLQisSznh3rql_UtgYHVzf9d2WM6PGZnXWSpe5Sc130_provenance.
- NP1260253.RAZ4beLQisSznh3rql_UtgYHVzf9d2WM6PGZnXWSpe5Sc130_assertion wasGeneratedBy ECO_0000203 NP1260253.RAZ4beLQisSznh3rql_UtgYHVzf9d2WM6PGZnXWSpe5Sc130_provenance.